Principal Investigator: Richard Rosenbaum, MD
Co-Investigators: Angela Senders, ND, Andrew Erlandsen, ND, & Heather Zwickey, PhD
Study Objectives: The purpose of this study is to determine whether a twelve week classic ketogenic diet (KD) is safely tolerated and of benefit in patients with Parkinson’s Disease (PD). The primary objective is to determine if PD patients have improvement in predominant symptoms and clinical findings over twelve weeks of a safely maintained KD that produces a sustained state of ketosis. The secondary objective is to determine if the classic KD alters L-dopa pharmacokinetics (PK) and thereby produces its therapeutic effects indirectly. The tertiary objective is to determine the feasibility and tolerability of the classic KD in longer term metabolism-based therapy. Cerebrospinal fluid (CSF) will be collected from as many of the participants as voluntarily consent for a sub-study on adenosine as a potential CSF biomarker for PD. CSF will be stored for future use so when novel biomarkers become available, their levels can be tested for changes in response to the KD. Collection of spinal fluid will be completely optional, not required for participation in the main study.